Lacktman Discusses CMS’ Physician-Texting Position Amid Reports of Banning mHealth Messaging
December 29, 2017
mHealthIntelligence
Partner Nate Lacktman was quoted in an mHealthIntelligence article, “CMS Clarifies Texting Rules Amid Rumors of mHealth Message Ban,” about the Centers for Medicare & Medicaid Services’ position on physician texting following reports that the agency was planning to ban the mHealth messaging platform. CMS Survey and Certification Group Director David Wright confirmed that texting patient information among patient care providers is permitted if sent via a secure messaging platform and texting patient orders is forbidden, regardless of the platform, and must only be submitted via a certified provider order entry.
mHealthIntelligence referenced Lacktman’s Dec. 29 LinkedIn post, in which he reiterated that the CMS hasn’t changed its position on physician texting and that it aligns with the Joint Commission’s position, which was last updated in 2016.
mHealthIntelligence referenced Lacktman’s Dec. 29 LinkedIn post, in which he reiterated that the CMS hasn’t changed its position on physician texting and that it aligns with the Joint Commission’s position, which was last updated in 2016.
People
Related News
June 10, 2025
In the News
Lynn Gandhi Sheds Light on Supreme Court Tax Ruling
Foley partner Lynn Gandhi commented in the Bloomberg Tax article "High Court’s Catholic Charities Case to Go Beyond Unemployment," sharing insight on the implications of the recent Supreme Court ruling in a tax case.
June 10, 2025
In the News
James McFall Joins Iconic Athletes and Leaders in Launch of Stanford Football Alumni United
Foley & Lardner LLP is proud to announce that partner James Carlos McFall is a founding member of Stanford Football Alumni United (SFAU), a newly formed coalition of former players and leaders committed to supporting Stanford Football’s continued growth and national competitiveness.
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."